Slingshot members are tracking this event:

Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Cancer”

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Our feedback to ICER on the NSCLC scoping document is intended to contribute our company’s perspective on the value that Immuno-Oncology agents, such as Opdivo, provide to patients impacted by NSCLC. We encourage ICER to incorporate the points we outlined in our response, including:
  • Removing the evaluation of PD-1 inhibitors for the treatment of first-line NSCLC from scope due to lack of randomized clinical data in this population among all manufacturers included in the review
  • Accounting for patients with driver mutations in the analysis
  • Separating assessments by histology (squamous and non-squamous) to account for difference in responses to treatment
  • Reflecting consistent and relevant patient populations among product comparisons
  • Maintaining consistency regarding long-term treatment duration assumptions (despite the lack of clinical trial stopping rules)
  • Including indirect measures of value (like quality of life) in the modeled assessment
  • Fully and proactively disclosing ICER’s modeling approach
  • Excluding budget impact in the assessment as it is not a measure of patient value
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Icer, Nsclc, Opdivo, Pd-1 Inhibitors